

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HLUNb | Copenhagen | DKK | Real-time | |
HLUNa | Copenhagen | DKK | Real-time | |
0ND5 | London | DKK | Real-time | |
LUNB | Vienna | EUR | Real-time |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Lars Soren Rasmussen | 63 | 2013 | Independent Chairman |
Lars Erik Holmqvist | 63 | 2015 | Director |
Jeremy Max Levin | 69 | 2017 | Independent Director |
Jeffrey Berkowitz | 56 | 2018 | Independent Director |
Santiago Arroyo | 62 | 2021 | Independent Director |
Camilla Gram Andersson | 50 | 2022 | Employee Representative Director |
Dorte Clausen | 38 | 2022 | Employee Representative Director |
Hossein Armandi | 60 | 2022 | Employee Representative Director |
Lasse Skibsbye | 39 | 2022 | Employee Representative Director |
Lene Skole-Sorensen | 63 | 2015 | Deputy Chairman |
Dorothea Wenzel | 53 | 2021 | Independent Director |
Jakob Riis | 57 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review